[go: up one dir, main page]

Zhang et al., 2018 - Google Patents

Pharmacokinetics of mycophenolate mofetil and development of limited sampling strategy in early kidney transplant recipients

Zhang et al., 2018

View HTML
Document ID
17830056664628404629
Author
Zhang J
Sun Z
Zhu Z
Yang J
Kang J
Feng G
Zhou L
Zuo L
Luo Y
Zhang X
Publication year
Publication venue
Frontiers in pharmacology

External Links

Snippet

The mycophenolate mofetil (MMF) dose management for optimization of post-transplant treatment especially the early postoperative phase has been well recognized. MMF is a pro- drug of mycophenolic acid (MPA) and is widely used in Chinese renal transplant patients …
Continue reading at www.frontiersin.org (HTML) (other versions)

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/92—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment; Prognosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N23/00—Investigating or analysing materials by the use of wave or particle radiation not covered by G01N21/00 or G01N22/00, e.g. X-rays or neutrons
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature

Similar Documents

Publication Publication Date Title
Zhang et al. Pharmacokinetics of mycophenolate mofetil and development of limited sampling strategy in early kidney transplant recipients
Chu et al. Clinical probes and endogenous biomarkers as substrates for transporter drug‐drug interaction evaluation: perspectives from the international transporter consortium
Nickel et al. Transport mechanisms at the pulmonary mucosa: implications for drug delivery
Chen et al. Associations between the maternal exposome and metabolome during pregnancy
Hall et al. Drug toxicity in the proximal tubule: new models, methods and mechanisms
Steg et al. Women and men with stable coronary artery disease have similar clinical outcomes: insights from the international prospective CLARIFY registry
Yang et al. Asparaginase may influence dexamethasone pharmacokinetics in acute lymphoblastic leukemia
Andrews et al. A population pharmacokinetic model to predict the individual starting dose of tacrolimus following pediatric renal transplantation
Bauer et al. Pgp‐Mediated Interaction Between (R)‐[11C] Verapamil and Tariquidar at the Human Blood–Brain Barrier: A Comparison With Rat Data
Abdelmoneim et al. Quantitative myocardial contrast echocardiography during pharmacological stress for diagnosis of coronary artery disease: a systematic review and meta-analysis of diagnostic accuracy studies
Ma et al. Evaluation of in vivo P-glycoprotein phenotyping probes: a need for validation
Jenkins et al. Phthalate-associated hypertension in premature infants: a prospective mechanistic cohort study
Pena et al. Effect of cytochrome P450 and ABCB1 polymorphisms on imatinib pharmacokinetics after single-dose administration to healthy subjects
Bosgra et al. To apply microdosing or not? Recommendations to single out compounds with non-linear pharmacokinetics
Kim et al. Assessment of induced CYP3A activity in pregnant women using 4β-hydroxycholesterol: cholesterol ratio as an appropriate metabolic marker
Shehab et al. Relationship between patient sex and serum tumor necrosis factor antagonist drug and anti-drug antibody concentrations in inflammatory bowel disease; a nationwide cohort study
Francke et al. The clinical validation of a dried blood spot method for simultaneous measurement of cyclosporine A, tacrolimus, creatinine, and hematocrit
Butelman et al. Re-evaluation of the KMSK scales, rapid dimensional measures of self-exposure to specific drugs: Gender-specific features
Mizuno et al. Developmental pharmacokinetics and age-appropriate dosing design of milrinone in neonates and infants with acute kidney injury following cardiac surgery
Alahmadi et al. Serum inhaled corticosteroid detection for monitoring adherence in severe asthma
Zhao et al. Principles of therapeutic drug monitoring
Dionisi et al. Pharmacokinetic evaluation of eltrombopag in ITP pediatric patients
Morse et al. Physiologically based pharmacokinetic modeling of transporter-mediated hepatic clearance and liver partitioning of OATP and OCT substrates in cynomolgus monkeys
Are et al. Primary sclerosing cholangitis limited to intrahepatic bile ducts has distinctly better prognosis
Liu et al. Population pharmacokinetic analysis of tacrolimus in adult Chinese patients with myasthenia gravis: a prospective study